All In Biotech

Drug Trial Radar · NCT07137104

Safety and Preliminary Effectiveness Study of Mesenchymal Stem Cells, HeXell-2020, in Patients With Stable Coronary Artery Disease

A Phase I/IIa Study to Investigate the Safety, Tolerability, and Preliminary Effectiveness of HeXell-2020 in Patients With Stable Coronary Artery Disease (CAD)

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

39

Planned (sponsor's estimate)

Start

Aug 27, 2026

Primary completion

Dec 31, 2028

Study completion Jul 31, 2029

Sponsor

Lead sponsor
Hexun Biosciences Co., LTD.Industry
Sponsor type
Industry
First posted
Aug 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/IIa study to investigate the safety, tolerability, and preliminary effectiveness of HeXell-2020 in patients with stable coronary artery disease (CAD). HeXell-2020 is an investigational drug product consisting of allogenic umbilical cord mesenchymal stem cells (UCMSCs) as the drug substance. All enrolled and eligible subjects will receive HeXell-2020 treatment.

Conditions

  • Coronary Artery Disease

Interventions

  • HeXell-2020Drug

    Phase I Cohort 1: HeXell-2020 with a total of 3 doses, 9x10\^7 cells/dose. Phase I Cohort 2: HeXell-2020 with a total of 6 doses, 9x10\^7 cells/dose. Phase IIa: RP2D from phase I.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of TEAE, SAE and SUSAR over the studyTime frame: Within the first year after cell transplantaion
  2. To determine the recommended phase II dose (RP2D) in Phase I studyTime frame: Within the first year after cell transplantaion
  3. Change in myocardial perfusion defect severity under the rest acquisition and pharmacological stress of dipyridamole in Phase IIa studyTime frame: Before first dosing and at 12 months post cell transplantaion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Far Eastern Memorial Hospital

    New Taipei City, Banqiao Dist, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.